BNP Paribas boosted its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 1,787.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 82,282 shares of the biotechnology company’s stock after buying an additional 77,922 shares during the period. BNP Paribas’ holdings in Biogen were worth $18,586,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in BIIB. Probity Advisors Inc. boosted its stake in Biogen by 3.6% during the third quarter. Probity Advisors Inc. now owns 1,183 shares of the biotechnology company’s stock worth $267,000 after buying an additional 41 shares during the period. Forum Financial Management LP raised its holdings in shares of Biogen by 2.4% in the third quarter. Forum Financial Management LP now owns 1,936 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 46 shares in the last quarter. Integrated Advisors Network LLC lifted its stake in Biogen by 3.5% in the third quarter. Integrated Advisors Network LLC now owns 1,403 shares of the biotechnology company’s stock worth $317,000 after acquiring an additional 48 shares during the period. Wedbush Securities Inc. lifted its stake in Biogen by 5.1% in the second quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 56 shares during the period. Finally, Parallel Advisors LLC lifted its holdings in Biogen by 1.5% during the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after buying an additional 65 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
Biogen Trading Up 1.0%
Shares of NASDAQ BIIB opened at $249.59 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.37 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $36.89 billion, a PE ratio of 106.66, a PEG ratio of 2.83 and a beta of 0.10. Biogen Inc. has a twelve month low of $160.36 and a twelve month high of $261.00. The stock has a fifty day simple moving average of $236.83 and a 200-day simple moving average of $206.86.
Analysts Set New Price Targets
A number of research firms recently commented on BIIB. JPMorgan Chase & Co. raised shares of Biogen from a “neutral” rating to an “overweight” rating and increased their target price for the company from $210.00 to $300.00 in a research report on Monday, October 12th. Seaport Research Partners upgraded shares of Biogen to an “outperform” rating in a research report on Monday, October 12th. Robert W. Baird raised their price target on shares of Biogen from $250.00 to $290.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. Wedbush lifted their price objective on shares of Biogen from $212.00 to $225.00 and gave the company a “neutral” rating in a report on Thursday, October 29th. Finally, Guggenheim raised their price objective on Biogen from $280.00 to $300.00 and gave the company a “buy” rating in a report on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.45.
View Our Latest Stock Report on BIIB
More Biogen News
Investors following BIIB have been watching these news items:
- Positive Sentiment: Biogen and Eisai reported that lecanemab slowed clinical decline over 18 months in an analysis of early Alzheimer’s patients with α-synuclein co-pathology. The subgroup results were exploratory and post hoc, but add supportive evidence for LEQEMBI’s potential reach. Article
- Positive Sentiment: Coverage also highlighted three-year real-world LEQEMBI data reporting slower Alzheimer’s progression, another potential support for the drug’s commercial prospects. Article
- Neutral Sentiment: Analyst commentary is mixed overall: one report says analysts remain moderately upbeat and notes BIIB has outpaced broad benchmarks over the past year, while another says Alzheimer’s progress and M&A-related growth expectations may already be reflected in the valuation. Analyst outlook Rating downgrade
Biogen Company Profile
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Recommended Stories
- Five stocks we like better than Biogen
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
